2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphatase
  5. Phosphatase Degrader

Phosphatase Degrader

Phosphatase Degraders (6):

Cat. No. Product Name Effect Purity
  • HY-148691
    PROTAC PTPN2 degrader-1
    		Degrader
    PROTAC PTPN2 degrader-1 (compound example 77) is a potent PTPN2 degrader. PROTAC PTPN2 degrader-1 has the potential for the research of cancer or metabolic disease.
  • HY-158381
    PROTAC PTP1B degrader 1
    		Degrader 99.37%
    PROTAC PTP1B degrader 1 is a CRBN-based PTP1B PROTAC degrader, with DC50 values of 0.2 μM (48 h) and 0.05 μM (72 h).
  • HY-181011
    PROTAC Cdc25 degrader-1
    		Degrader
    PROTAC Cdc25 degrader-1 (Compound D3) is an efficient Cdc25 PROTAC degrader. Its DC50 values for Cdc25A, Cdc25B, and Cdc25C are 0.97, 2.02, and 4.67 μM respectively. PROTAC Cdc25 degrader-1 induces cell cycle arrest and apoptosis in cancer cells and inhibits cell migration ability. PROTAC Cdc25 degrader-1 significantly increases the ROS level. PROTAC Cdc25 degrader-1 can be used for the study of colorectal adenocarcinoma.
  • HY-160151
    TP1L
    		Degrader
    TP1L is a potent and selective T-cell protein tyrosine phosphatase (TC-PTP) PROTAC degrader, with a DC50 value of 35.8 nM. TP1L elevates the phosphorylation level of TC-PTP substrates including pSTAT1 and pJAK1. TP1L selectively enhances IFN-γ signaling and increases MHC-I expression. TP1L activates TCR signaling through increases phosphorylation of LCK. TP1L enhances CAR-T cell mediated tumor killing efficacy through activation of the CAR-T cells. TP1L can be used for the study of cancer. (Pink: TC-PTP ligand: (HY-138964), Blue: E3 ligase CRBN Ligand (HY-A0003), Black: Linker: (HY-140002)).
  • HY-184259
    PTPN2 ligand 4
    		Degrader
    PTPN2 ligand 4 is a PTPN2 ligand and can be used for the synthesis of PROTACs, such as PD-305 (HY-183937).
  • HY-183937A
    PD-305
    		Degrader
    PD-305 is a selective PTPN2 PROTAC degrader, with DC50 values of 0.25 nM and 5.11 nM against PTPN2 and PTPN1, respectively. PD-305 enhances IFN-γ-induced STAT1 phosphorylation, inhibits the proliferation of IFN-γ-stimulated colorectal cancer cells, promotes CD8+ T cell activation, enhances the tumor-killing activity of T cells, and suppresses tumor growth in mouse models. PD-305 can be used for the research of colorectal cancer.